Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 15/20 | 0.40 |
| ▸ | JUN | P05412 | 14/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 14/20 | 0.40 |
| ▸ | RELA | Q04206 | 14/20 | 0.40 |
| ▸ | XPO1 | O14980 | 4/20 | 0.39 |
| ▸ | ATF1 | P18846 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | BCR | P11274 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL653208 | 0.74 | NFKB1 (0.40) | NFKB1JUNNFKB2RELAXPO1 | |
| SCHEMBL16885200 | 0.68 | MAPT (0.40) | L3MBTL1KMT2A | |
| SCHEMBL4089231 | 0.67 | CES2 (0.44) | — | |
| SCHEMBL12413632 | 0.67 | SMN1; SMN2 (0.42) | L3MBTL1KMT2A | |
| SCHEMBL1554935 | 0.64 | SMN1; SMN2 (0.40) | L3MBTL1KMT2A | |
| SCHEMBL30577163 | 0.64 | SMN1; SMN2 (0.44) | ABL1BCRL3MBTL1KMT2A | |
| SCHEMBL5335551 | 0.64 | SMN1; SMN2 (0.44) | ABL1BCRL3MBTL1KMT2A | |
| Ammonia Solution, Strong SCHEMBL15437905 | 0.62 | SMN1; SMN2 (0.33) | NFKB1L3MBTL1KMT2A | |
| SCHEMBL7253697 | 0.62 | ADORA2A (0.46) | NFKB1JUNNFKB2RELAMEN1 | |
| SCHEMBL15282472 | 0.62 | SMN1; SMN2 (0.41) | NFKB1JUNNFKB2RELAXPO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835430-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20140031350-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031350-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | FCER2, FCGR1A, FCGR2A | NFKB1 774/4885JUN 1486/4885NFKB2 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.